TVTX Earnings Prediction
The chart below shows how TVTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TVTX sees a +1.64% change in stock price 10 days leading up to the earnings, and a -6.84% change 10 days following the report. On the earnings day itself, the stock moves by +1.94%. This data can give you a slight idea of what to expect for the next quarter's release.
TVTX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
74.79M
65.98%
18.90%
Gross Margin
96.59%
7.48%
-0.84%
Operating Margin
-79.34%
-56.85%
-10.92%
Net Margin
-80.59%
-59.01%
-7.42%
EPS
-0.72
-38.98%
2.86%
No Data Available
TVTX Earnings Analysis
Travere Therapeutics Inc Corporation (TVTX.O) Earnings Conference Call
Positive
FDA Approval Milestone: FILSPARI received full FDA approval for IgA nephropathy in September, marking a significant milestone for the company and its patients.
Net Sales Surge: In Q4, net sales of FILSPARI grew nearly 40% compared to Q3, indicating strong demand following full approval.
New Drug Application Plans: The company plans to submit a supplemental New Drug Application (sNDA) for FILSPARI for a potential FSGS indication, supported by compelling clinical data.
IgAN Therapy Superiority: FILSPARI is positioned as a foundational therapy for IgAN, demonstrating superiority over historical standard of care with robust long-term efficacy data.
FILSPARI Adoption in Treatment: Physicians are increasingly recognizing FILSPARI as a foundational treatment, with updated KDIGO guidelines encouraging earlier diagnosis and treatment.
Exceptional Patient Growth: The commercial performance of FILSPARI in Q4 was exceptional, with a 37% increase in new patient start forms compared to the previous quarter.
FILSPARI Sales Growth: The company achieved approximately $50 million in net product sales of FILSPARI for Q4, reflecting strong growth and adoption in the IgAN community.
Guideline Impact on Treatment: The updated draft KDIGO guidelines are expected to drive physician behavior towards earlier treatment and access to FILSPARI.
Strong Financial Position: The company has a strong financial position with $370.7 million in cash and marketable securities, supporting future growth initiatives.
Negative
Quarterly Net Loss Comparison: Net loss for Q4 2024 was $60.3 million, a significant loss compared to $90.2 million in Q4 2023, indicating ongoing financial challenges.
Net Loss Increase: Full year net loss for 2024 was $321.5 million, a substantial increase from $111.4 million in 2023, highlighting worsening financial performance year-over-year.
Net Sales Decline Analysis: The decrease in net product sales for Thiola in Q4 2024 due to generic competition suggests vulnerability in this segment of the business.
Sales Growth Challenges: Despite growth in FILSPARI sales, the company anticipates further headwinds in 2025 due to increased competition and market dynamics, particularly in the IgA nephropathy segment.
Other Income Decline: The company reported a total other income net of only $0.4 million in Q4 2024, a significant drop from $5.7 million in Q4 2023, indicating reduced financial flexibility.
Profitability Pressure Ahead: The anticipated moderate increase in gross to net discounts for 2025 suggests potential pressure on profitability moving forward.
TVTX FAQs
How does TVTX typically perform around its earnings report dates?
Is Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TVTX Earning Call Sentiment
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript
TVTX.O
-1.47%Positive
The earnings call presents a mixed picture: strong revenue growth and FILSPARI's successful launch are positive, but significant net losses and lack of shareholder return plans are concerning. The Q&A highlights confidence in FILSPARI despite competition, but also reveals uncertainties, such as guidance delays and financial sustainability. No new partnerships or shareholder incentives were announced, and financial guidance remains vague. Given these factors, a neutral stock price reaction is expected.
